The Phase III trials of Bharat Biotech’s COVID-19 Vaccine ‘COVAXIN’ began in Haryana on Friday. The first dose of vaccine was administered to Haryana’s Health Minister Anil Vij at the Civil Hospital, Ambala Cantt. He was vaccinated under the supervision of PGI Rohtak’s team. He was then kept under observation for half an hour. In Haryana, the responsibility of Phase III trials of ‘Covaxin’ has been given to PGIMS. Health Minister Anil Vij was proposed to be included in this test.
ICMR and Bharat Biotech jointly developing ‘Covaxin’:
The third phase trials of ‘Covaxin’ being developed under Bharat Biotech and Indian Council of Medical Research (ICMR), will also be conducted on people suffering from kidney, liver and heart diseases. PGIMS will start trials on 1,000 volunteers. Volunteers over 18 years of age will be given a 6 mg dose of ‘Covaxin’. Experts believe that Bharat Biotech’s ‘Covaxin’ will be more successful than the other vaccines being developed worldwide as it is developed on the basis of the strain of the virus found in the country.
Phase III trials of ‘Coxavin’ will be conducted on 25,800:
Let us tell you that the phase III trials will be conducted on 25,800 volunteers at a total of 21 centers. According to the test team, after 42 days the antibody status in the body will be measured. If antibodies developed even after this time limit, then the trial will be considered successful. University Vice-Chancellor Dr. OP Kalra said that if the test is successful, then the vaccine may be ready by April-May.
45,882 reported in India in the last 24 hours:
India on Friday reported 45,882 new cases of coronavirus in the last 24 hours. With this, the total number of infected people has crossed 9 million in the country. At the same time, 44,807 people have recovered or cured in the last 24 hours. With this, the number of people recovering in the country has exceeded 84.28 lakhs. At the national level, the rate of recovery has increased to 93.60 percent.